The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation.”

IGCS is honored to have had Professor Tasuku Honjo (Kyoto University) as the Presidential Plenary Lecture at the recent IGCS Biennial Meeting in Kyoto, Japan. In Prof. Honjo’s lecture “Future of Cancer Immunotherapy by PD-1 Blockade” he spoke about his work in discovering the T-cell protein, PD-1 acts as a brake on the immune system.

This discovery, as well as Professor James Allison’s (University of California) work with a ‘checkpoint’ protein, CTLA-4, have led to a new pillar in cancer therapy known as immune checkpoint therapy. Trials are now underway to evaluate the efficacy of checkpoint therapy against most types of cancer, and scientists are testing numerous other checkpoint proteins to see if they could act as targets.

 

Read more about the Nobel Prize winners and their ground breaking work:

New York Times Story

TIME Story

Nature International Journal of Science Story

 

Photographs from Prof. Tasuku Honjo’s lecture at the IGCS Meeting held in Kyoto, Japan on Sept. 14, 2018.